Article

Bacterial cellulose-based materials and medical devices: current state and perspectives.

University of Virginia School of Medicine, PO Box 800233, Charlottesville, VA 22908-0233, USA.
Applied Microbiology and Biotechnology (Impact Factor: 3.81). 09/2011; 91(5):1277-86. DOI: 10.1007/s00253-011-3432-y
Source: PubMed

ABSTRACT Bacterial cellulose (BC) is a unique and promising material for use as implants and scaffolds in tissue engineering. It is composed of a pure cellulose nanofiber mesh spun by bacteria. It is remarkable for its strength and its ability to be engineered structurally and chemically at nano-, micro-, and macroscales. Its high water content and purity make the material biocompatible for multiple medical applications. Its biocompatibility, mechanical strength, chemical and morphologic controllability make it a natural choice for use in the body in biomedical devices with broader application than has yet been utilized. This paper reviews the current state of understanding of bacterial cellulose, known methods for controlling its physical and chemical structure (e.g., porosity, fiber alignment, etc.), biomedical applications for which it is currently being used, or investigated for use, challenges yet to be overcome, and future possibilities for BC.

8 Followers
 · 
165 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the present study, purified wet bacterial cellulose was disrupted into cellulose aqueous suspensions (0.5%, w/v) and then homogenized by 10 passes at 0, 200, 400 and 600 bar respectively. In order to evaluate the effects of high pressure homogenization (HPH) on bacterial cellulose aqueous suspensions, morphology, rheology, stability, texture, water holding capacity (WHC), water swelling ability (WSA) and water release rate (WRR) were investigated. Morphological analysis by atomic force microscopy revealed changes in microstructure and dispersion of cellulose ribbons after HPH treatment. The diameter of micro-fibril ribbons decreased from 95.6 nm to 60.3 nm with increasing pressure up to 600 bar. The rheology results suggested that all the suspensions displayed a shear thinning behaviour, moreover the suspensions treated by HPH showed 3 regions (shear thinning region, plateau region and shear thinning region again) and the flow curves followed the Herschel–Bulkley model. Furthermore, the stability and textural properties of the suspensions were enhanced after HPH treatment. Additionally, WHC and WSA of cellulose suspensions displayed high stability and the WRR increased after HPH treatment during storage.
    Food Hydrocolloids 10/2014; 44. DOI:10.1016/j.foodhyd.2014.10.019 · 4.28 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Stereospecific nucleation of mesoporous hybrid microspheres composed of CaCO3 and carrageenan was appended to one side of bacterial cellulose membrane synthesized in static cultures of Gluconacetobacter hansenii to develop an implantable drug delivery device. The synthesis of the hybrid microparticles proceeds by self-assembly mechanism in presence of calcium and contains tailorable amounts of doxorubicin. However, in absence of the particles, doxorubicin was distributed along the BC film, but without control release of drug. Infrared spectroscopy, confocal and scanning electron microscopies analyses demonstrate that the doxorubicin is entrapped inside the hybrid particles with approximately 80% drug loading compared to the 11% obtained for native bacterial cellulose. Doxorubicin content in the hybrid particles can be increased by a factor of ten (from 258.6 to 2,586.3 nmol ml-1), and also by the quantities of particles regulated by the CaCO3-carrageenan content and the physicochemical microenvironment. The hybrid BC system can be considered as smart device since the kinetic release of doxorubicin from the hybrid cellulose system rise from 1.50 to 2.75 μg/membrane/day when the pH decreases from 7.4 to 5.8 at 37ºC, a pathological simulated environment. The hybrid microparticle system can be potentially used as an implantable drug delivery system for personalized oncological therapies.
    Journal of applied biomedicine 03/2015; DOI:10.1016/j.jab.2015.03.004 · 1.78 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tissue engineering provides a promising alternative therapy to the complex surgical reconstruction of auricular cartilage by using ear-shaped autologous costal cartilage. Bacterial nanocellulose (BNC) is proposed as a promising scaffold material for auricular cartilage reconstruction, as it exhibits excellent biocompatibility and secures tissue integration. Thus, this study evaluates a novel bilayer BNC scaffold for auricular cartilage tissue engineering. Bilayer BNC scaffolds, composed of a dense nanocellulose layer joined with a macroporous composite layer of nanocellulose and alginate, were seeded with human nasoseptal chondrocytes (NC) and cultured in vitro for up to 6 weeks. To scale up for clinical translation, bilayer BNC scaffolds were seeded with a low number of freshly isolated (uncultured) human NCs combined with freshly isolated human mononuclear cells (MNC) from bone marrow in alginate and subcutaneously implanted in nude mice for 8 weeks. 3D morphometric analysis showed that bilayer BNC scaffolds have a porosity of 75% and mean pore size of 50 ± 25 μm. Furthermore, endotoxin analysis and in vitro cytotoxicity testing revealed that the produced bilayer BNC scaffolds were non-pyrogenic (0.15 ± 0.09 EU/ml) and non-cytotoxic (cell viability: 97.8 ± 4.7%). This study demonstrates that bilayer BNC scaffolds offer a good mechanical stability and maintain a structural integrity while providing a porous architecture that supports cell ingrowth. Moreover, bilayer BNC scaffolds provide a suitable environment for culture-expanded NCs as well as a combination of freshly isolated NCs and MNCs to form cartilage in vitro and in vivo as demonstrated by immunohistochemistry, biochemical and biomechanical analyses. Copyright © 2014 Elsevier Ltd. All rights reserved.
    Biomaterials 03/2015; 44:122-133. DOI:10.1016/j.biomaterials.2014.12.025 · 8.31 Impact Factor